Arbutus Biopharma Gross Profit vs. Shares Outstanding
| ABUS Stock | USD 3.37 0.07 2.03% |
Gross Profit | First Reported 2000-03-31 | Previous Quarter 1.4 M | Current Value 1.3 M | Quarterly Volatility 146.9 B |
For Arbutus Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Arbutus Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Arbutus Biopharma Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Arbutus Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Arbutus Biopharma Corp over time as well as its relative position and ranking within its peers.
Arbutus |
Arbutus Biopharma's Revenue Breakdown by Earning Segment
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.43) | Revenue Per Share | Quarterly Revenue Growth (0.71) | Return On Assets | Return On Equity |
The market value of Arbutus Biopharma Corp is measured differently than its book value, which is the value of Arbutus that is recorded on the company's balance sheet. Investors also form their own opinion of Arbutus Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arbutus Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arbutus Biopharma's market value can be influenced by many factors that don't directly affect Arbutus Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arbutus Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Arbutus Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Arbutus Biopharma Corp Shares Outstanding vs. Gross Profit Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Arbutus Biopharma's current stock value. Our valuation model uses many indicators to compare Arbutus Biopharma value to that of its competitors to determine the firm's financial worth. Arbutus Biopharma Corp is rated fifth in gross profit category among its peers. It is rated third in shares outstanding category among its peers . At this time, Arbutus Biopharma's Gross Profit is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Arbutus Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Arbutus Shares Outstanding vs. Gross Profit
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Arbutus Biopharma |
| = | (56.05 M) |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Arbutus Biopharma |
| = | 189.49 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Arbutus Shares Outstanding Comparison
Arbutus Biopharma is currently under evaluation in shares outstanding category among its peers.
Arbutus Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Arbutus Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Arbutus Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Arbutus Biopharma's change in net profit over the period of time. It can combine multiple indicators of Arbutus Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -43.6 M | -41.4 M | |
| Operating Income | -70.3 M | -73.8 M | |
| Net Loss | -65.6 M | -68.8 M | |
| Net Loss | -67.9 M | -71.3 M | |
| Income Before Tax | -65.6 M | -68.8 M | |
| Total Other Income Expense Net | 4.7 M | 5 M | |
| Net Loss | -62.5 M | -65.6 M | |
| Income Tax Expense | (0.90) | (0.94) | |
| Non Operating Income Net Other | 2.5 M | 2.4 M | |
| Interest Income | 4.6 M | 3.7 M | |
| Net Interest Income | 4 M | 4.2 M | |
| Change To Netincome | 2 M | 1.9 M | |
| Net Loss | (0.40) | (0.41) | |
| Income Quality | 1.36 | 0.83 | |
| Net Income Per E B T | 0.96 | 0.76 |
Arbutus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Arbutus Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Arbutus Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Arbutus Biopharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Arbutus Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Use Investing Themes to Complement your Arbutus Biopharma position
In addition to having Arbutus Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Recycling Thematic Idea Now
Recycling
West management companies as well as entities specializing in pollution control and recycling. The Recycling theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recycling Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.